BMRN BIOMARIN PHARMACEUTICAL INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1048477 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.1%
TTM net income YoY-103.7%
TTM EPS YoY-103.7%
Revenue 3-yr CAGR16.5%
Net income 3-yr CAGR—
Margins
Gross margin76.0%
Operating margin3.1%
Net margin-0.5%
FCF margin15.3%
EBITDA margin4.7%
Returns
ROE-0.3%
ROA-0.2%
ROIC (approx.)0.8%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets45.9%
Debt / equity0.67x
Current ratio2.44x
Interest coverage0.89x
Cash quality & payout
Operating cash flow / net income-35.40x
Accruals ratio-7.3%
Payout ratio—
Capex / revenue3.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.02B | $989.71M | $766.21M | $874.57M | $776.13M | $825.41M | $745.14M | $747.31M |
| Cost of revenue | $205.42M | $202.79M | $195.00M | $275.71M | $140.09M | $150.09M | $151.56M | $136.14M |
| Gross profit | $819.23M | $786.91M | $571.21M | $598.86M | $636.05M | $675.32M | $593.59M | $611.17M |
| R&D expense | $180.53M | $206.95M | $178.80M | $192.41M | $188.51M | $161.31M | $158.73M | $173.51M |
| SG&A expense | $333.64M | $395.55M | $258.29M | $446.21M | $268.42M | $232.28M | $206.12M | $266.61M |
| Operating income | -$82.08M | $110.92M | $129.64M | -$44.61M | -$46.69M | $276.89M | $223.89M | $161.41M |
| Interest expense | $55.23M | $60.73M | $9.57M | $2.78M | $2.39M | $2.39M | $2.39M | $2.58M |
| Pretax income | -$131.77M | $61.38M | $141.20M | -$27.15M | -$26.32M | $297.87M | $238.09M | $169.64M |
| Income tax | -$8.94M | $16.62M | $35.68M | $19.42M | $4.42M | $57.34M | $52.40M | $44.70M |
| Net income | -$122.83M | $44.76M | $105.53M | -$46.57M | -$30.74M | $240.53M | $185.69M | $124.94M |
| EBITDA | -$71.88M | $120.52M | $146.05M | -$24.17M | -$36.09M | $287.49M | $245.96M | $185.01M |
| EPS (basic) | -0.63 | 0.23 | 0.55 | — | -0.16 | 1.25 | 0.97 | — |
| EPS (diluted) | -0.63 | 0.23 | 0.54 | — | -0.16 | 1.23 | 0.95 | — |
| Weighted avg. shares (diluted) | 193.59M | 194.47M | 197.67M | — | 192.03M | 197.09M | 196.47M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $736.01M | $874.00M | $2.22B | $1.31B | $1.25B | $1.21B | $1.05B | $942.84M |
| Short-term investments | $0 | $0 | $0 | $248.93M | $227.73M | $218.31M | $223.53M | $194.86M |
| Receivables | $1.08B | $1.06B | $903.91M | $908.21M | $790.27M | $855.86M | $739.18M | $660.53M |
| Inventory | $1.80B | $1.78B | $1.27B | $1.30B | $1.38B | $1.34B | $1.27B | $1.23B |
| Current assets | $3.92B | $3.97B | $4.61B | $3.95B | $3.85B | $3.81B | $3.47B | $3.23B |
| PP&E, net | $980.08M | $989.99M | $958.07M | $952.51M | $1.04B | $1.03B | $1.03B | $1.04B |
| Goodwill | $666.37M | $655.75M | $196.20M | $196.20M | $196.20M | $196.20M | $196.20M | $196.20M |
| Intangibles | $4.78B | $4.88B | $204.66M | $213.84M | $233.11M | $239.62M | $247.35M | $255.28M |
| Total assets | $11.57B | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B |
| Current liabilities | $1.60B | $1.66B | $793.15M | $759.03M | $798.44M | $684.25M | $628.21M | $606.99M |
| Short-term debt | $658.72M | $658.20M | — | $0 | — | — | — | — |
| Long-term debt | $3.51B | $3.53B | $1.43B | $597.18M | — | — | — | — |
| Total debt | $4.17B | $4.19B | $1.43B | $597.18M | — | — | — | — |
| Total liabilities | $5.31B | $5.40B | $2.38B | $1.51B | $1.56B | $1.43B | $1.35B | $1.33B |
| Shareholders' equity | $6.26B | $6.32B | $6.21B | $6.09B | $6.06B | $6.03B | $5.79B | $5.66B |
| Net debt | $3.44B | $3.31B | -$792.15M | -$714.50M | — | — | — | — |
| Shares outstanding | 193.68M | 193.54M | 193.27M | 192.30M | 192.10M | 192.00M | 191.76M | 190.76M |
| Cash flow statement | ||||||||
| Operating cash flow | $188.21M | $168.11M | $220.65M | $99.64M | $368.69M | $185.27M | $174.39M | $185.63M |
| Capital expenditure | $28.29M | $28.82M | $20.92M | $40.72M | $28.45M | $17.10M | $16.77M | $19.53M |
| Free cash flow | $159.92M | $139.29M | $199.73M | $58.92M | $340.24M | $168.17M | $157.63M | $166.10M |
| Investing cash flow | -$306.90M | -$5.10B | $725.53M | -$42.45M | -$330.96M | -$12.59M | -$28.24M | $76.40M |
| Financing cash flow | -$18.83M | $2.74B | $813.17M | $3.16M | -$2.17M | -$4.60M | -$38.78M | $2.86M |
| Depreciation & amortization | $10.20M | $9.60M | $16.41M | $20.44M | $10.60M | $10.60M | $22.07M | $23.61M |
| Stock-based compensation | $53.53M | $75.69M | $43.46M | $46.91M | $49.27M | $47.53M | $37.70M | $51.92M |
Free plan shows the latest 8 periods; Pro shows all 71 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.